PENPACT-1 had a 2 2 factorial design , randomizing HIV-infected children to start protease inhibitor ( PI ) versus nonnucleoside reverse transcriptase inhibitor ( NNRTI ) - based ART , and switch at a 1000 copies/mL versus 30,000 copies/mL threshold .